Oncolytics Biotech Inc ONCY

Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

[Noteable]

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?threadid=36048690

[Noteable]

Besides the ADC Enhertu being approved for multiple stages of ER+/Her2 (+/-) (posotove/negative) breast cancer,  ONCY's decision to target the HER2 failed breast cancer patient population with pelareorep + paclitaxel may have been also influenced by today's Roche/Genentech's breakthrough therapy announcement involving  ER+/Her2- (negative) breast cancer May 21, 2024

[Noteable]

Should read: ' ...ER+/Her2 (+/-) (positive/negative) breast cancer..."

[Noteable]

Regardless of whatever influenced ONCY's decision to target the HER2 failed breast cancer patient population, the HER2 failed population is a large and conclusively identifiable population since they are the same who had been previously identified as having HER2 (positive/negative) breast cancer, treated with an ADC therapy and then ultimately failing on this same therapy. These failed breast

[Noteable]

ONCY's Phase 2 Bracelet-1 study 2 year breast cancer patient overall survival (OS) milestone being reached at the end of this month- May 2024.

[Noteable]

Key one (1) year biomarker and safety findings of ONCY's Phase 2 Bracelet-1 breast cancer study:  Association between T cell expansion and efficacy measures:  A statistically significant increase in T cell fraction, a measure of T cell expansion, was observed in cohort 2 (paclitaxel + pelareorep) but not cohort 3 (paclitaxel + pelareorep + avelumab) Generally favorable and

[Noteable]

May 21, 2024 - - Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing. The decision is based on research showing the medicine, called inavolisib, could offer a more effective first treatment option for women with a ER+/HER2 - (negative) breast cancer mutation

[Noteable]

ONCY's IND213 breast cancer study conducted by the Canadian Trials Group - found that patients with increased age, better performance status (PS), no prior paclitaxel therapy and mutations in TP53, PTEN, AKTI and KIT had longer OS, while those with PIK3CA, APC and ATM mutations had shorter OS.

[Noteable]

May 29, 2024 - Roche/Genentech's priority review for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant was evaluated in adult patients with P1K3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer,is based on the positive Phase III

[Noteable]

Inavolisib is currently being investigated in three company-sponsored Phase III clinical studies (INAVO120, INAVO121, INAVO122) in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations.  https://www.biospace.com/article/releases/fda-grants-priority-review-to-genentech-s-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a

[Noteable]

Comparing Roche's inavolisib's + palbociclib and fulvestrant combination Phase 3 results to ONCY's pelareorep + paclitaxel Phase 2 results ... The results showed the inavolisib-based regimen more than doubled progression-free survival (PFS), reducing the risk of disease worsening or death by 57% compared to palbociclib and fulvestrant alone (15.0 months vs. 7.3 months

[canadafan]

I agree 100%, clearly an advantage utilizing Pela as a cotherapy. the numbers you indicated are substantial. check in box